Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Changes in Myocardial Iron Content Following Administration of Intravenous Iron
2016-004194-40Phase 4Completed
- Sponsor
- INCLIVA Biomedical Research Institute
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ferric carboxymaltose in chronic heart failure (CHF), sponsored by INCLIVA Biomedical Research Institute. Primary endpoints: Changes in myocardial iron content by T2* CMR at day 7 and Changes in myocardial iron content by T2* CMR at day 30. Started Dec 2016; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on 2016-004194-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004194-40.